Prometheus Biosciences to Participate at the 11th Annual SVB Leerink Global Healthcare Conference
February 07, 2022 08:00 ET
|
Prometheus Biosciences
SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery,...
Prometheus Biosciences Provides Corporate Updates at the 40th Annual J.P. Morgan Healthcare Conference
January 12, 2022 08:30 ET
|
Prometheus Biosciences
- Fast Track Designation granted from U.S. Food and Drug Administration for PRA023 for the treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) - - New patent granted for...
Prometheus Biosciences to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference
January 05, 2022 08:30 ET
|
Prometheus Biosciences
SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery,...
Prometheus Biosciences and Dr. Falk Pharma Advance PR600 and Trigger Final Preclinical Milestone Payment
January 03, 2022 08:00 ET
|
Prometheus Biosciences
SAN DIEGO, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery,...
Prometheus Biosciences Reports Positive Topline Phase 1 Data on Lead Therapeutic Candidate PRA023; Expands Indications to Include Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
December 07, 2021 07:00 ET
|
Prometheus Biosciences
Phase 1 trial achieved primary objective of safety and tolerability and demonstrated favorable outcomes on other key endpoints, including target engagement and immunogenicity Discussion of Phase 1...
Prometheus Biosciences Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Progress
November 12, 2021 08:00 ET
|
Prometheus Biosciences
- Full clinical trial results from Phase 1a trial of PRA023 and announcement of a third Phase 2 indication for PRA023 expected in fourth quarter 2021 - - Enrollment on track for Phase 2 in...
Prometheus Biosciences to Present at Jefferies Virtual Next Generation IBD Therapeutics Summit
October 12, 2021 16:01 ET
|
Prometheus Biosciences
SAN DIEGO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), today announced that Mark McKenna, Chairman and Chief Executive Officer and Allison Luo, M.D., Chief Medical...
Prometheus Biosciences Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Progress
August 11, 2021 16:01 ET
|
Prometheus Biosciences
- Initiated Phase 2 study of PRA023 and its companion diagnostic in Ulcerative Colitis (UC) and Phase 2a study of PRA023 and its companion diagnostic in Crohn’s disease (CD) - - Phase 1a trial...
Prometheus Biosciences Announces Initiation of Global Phase 2 Clinical Trial of PRA023 in Moderate-to-Severe Ulcerative Colitis (UC)
July 19, 2021 08:00 ET
|
Prometheus Biosciences
-First precision approach to IBD by utilizing a companion diagnostic to identify patients- -Phase 2a initiation in Crohn’s Disease on track for 3rd Quarter 2021- - Further details to be provided at...
Fred Hassan, Former CEO of Schering-Plough and Former Chairman of Bausch & Lomb, Joins Prometheus Biosciences Board
May 17, 2021 08:00 ET
|
Prometheus Biosciences
SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery,...